Immuron Sees Substantial Sales Growth in FY23 Driven by Resurgence in Travel (ASX:IMC)

Immuron Limited (ASX: IMC; NASDAQ: IMRN), the Melbourne-based biopharmaceutical firm, has reported a stellar performance for FY23 with a 136% surge in global sales compared to FY22.

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.